Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
3.380
-0.210 (-5.85%)
At close: Dec 24, 2025, 1:00 PM EST
3.550
+0.170 (5.03%)
After-hours: Dec 24, 2025, 4:59 PM EST
Imunon Employees
Imunon had 25 employees as of December 31, 2024. The number of employees decreased by 8 or -24.24% compared to the previous year.
Employees
25
Change (1Y)
-8
Growth (1Y)
-24.24%
Revenue / Employee
n/a
Profits / Employee
-$573,176
Market Cap
10.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | -8 | -24.24% |
| Dec 31, 2023 | 33 | 2 | 6.45% |
| Dec 31, 2022 | 31 | 2 | 6.90% |
| Dec 31, 2021 | 29 | 2 | 7.41% |
| Dec 31, 2020 | 27 | -2 | -6.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMNN News
- 5 weeks ago - Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript - Seeking Alpha
- 6 weeks ago - IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer - GlobeNewsWire
- 6 weeks ago - IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer - GlobeNewsWire
- 6 weeks ago - IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment - GlobeNewsWire
- 7 weeks ago - IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025 - GlobeNewsWire
- 7 weeks ago - IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer - GlobeNewsWire